180 Life Sciences CORP 8-K filings

180 Life Sciences Corp. has appointed two new independent directors, Omar Jimenez and Ryan L. Smith, while also restructuring its board committees and accepting the resignation of Sir Marc Feldmann.

180 Life Sciences Corp. reports the exercise of pre-funded warrants resulting in the issuance of common stock and the elimination of all outstanding pre-funded warrants.

180 Life Sciences Corp. reports the exercise of warrants resulting in the issuance of 64,684 shares of common stock after a reverse stock split.

180 Life Sciences Corp. has appointed Blair Jordan to its Board of Directors, effective February 28, 2024, and temporarily set the board size at four members.

180 Life Sciences Corp. has executed a 1-for-19 reverse stock split to meet the NASDAQ's minimum bid price requirement, effective February 28, 2024.

180 Life Sciences Corp. will implement a 1-for-19 reverse stock split effective February 28, 2024, to meet Nasdaq's minimum bid price requirement.

180 Life Sciences has won a partial summary judgment requiring its insurers to cover defense costs for former executives in an SEC subpoena matter, pending a trial in 2025.

180 Life Sciences Corp. stockholders approved an amendment to the company's incentive plan, a reverse stock split, and the issuance of shares upon the exercise of warrants at a special meeting on February 16, 2024.

180 Life Sciences Corp. announced that no management bonuses will be awarded for 2022, 2023, or accrued for 2024, and provided a revised executive compensation table for 2022.

180 Life Sciences Corp. has amended employment and consulting agreements with key personnel, implementing substantial salary reductions effective January 1, 2024, to conserve cash pending a $5 million funding raise.

180 Life Sciences Corp. has been granted an extension by Nasdaq until May 13, 2024, to regain compliance with minimum stockholders' equity requirements after reporting a deficit.